ibuprofen has been researched along with Cardiovascular Diseases in 56 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 9.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 9.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "Nonsteroidal antiinf lammatory drugs (NSAIDs) remain the mainstay of the pharmacologic management for relieving osteoarthritis pain, and low-dose aspirin is often prescribed to osteoarthritis patients who are at high risk of cardiovascular disease (CVD)." | 8.31 | Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis. ( Lane, NE; Lei, G; Li, X; Wei, J; Zeng, C; Zhang, Y, 2023) |
| " We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial." | 7.83 | Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Gonzalez-Valcarcel, J; Hennerici, MG; Labreuche, J; Mattle, HP; Rothwell, PM; Sissani, L; Steg, PG; Vicaut, E, 2016) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs)." | 6.74 | Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. ( Becker, MC; Borer, JS; Graham, DY; Husni, ME; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Mascette, AM; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, TH; Wisniewski, L; Wolski, K; Yeomans, ND, 2009) |
| "Twenty-four thousand eighty-one patients who required NSAIDs for osteoarthritis or rheumatoid arthritis (RA) and had increased CV risk randomly received celecoxib, ibuprofen, or naproxen." | 5.51 | Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. ( Bao, W; Davey, DA; Husni, E; Libby, P; Lüscher, TF; Nissen, SE; Obeid, S; Ruschitzka, F; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Xia, F, 2022) |
| "Metformin is an antihyperglycemic agent commonly used in diabetic patients." | 5.37 | The nephrologist's role in metformin-induced lactic acidosis. ( Basterrechea, MA; de Arriba, G; Gómez-Navarro, L; Hernández-Sevillano, B; Pérez del Valle, KM; Rodríguez-Palomares, JR; Sánchez-Heras, M; Tallón, S; Torres-Guinea, M, 2011) |
| "To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)." | 5.27 | Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 5.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 5.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "Nonsteroidal antiinf lammatory drugs (NSAIDs) remain the mainstay of the pharmacologic management for relieving osteoarthritis pain, and low-dose aspirin is often prescribed to osteoarthritis patients who are at high risk of cardiovascular disease (CVD)." | 4.31 | Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis. ( Lane, NE; Lei, G; Li, X; Wei, J; Zeng, C; Zhang, Y, 2023) |
| " We used a Mantel-Haenszel method to obtain odds ratios (ORs) of the association between NSAID use (ibuprofen, naproxen, or diclofenac) and MACE (myocardial infarction, ischemic stroke, heart failure, or all-cause death)." | 4.31 | Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study. ( Bonnesen, K; Ehrenstein, V; Grønkjær, MS; Hallas, J; Lash, TL; Pedersen, L; Schmidt, M; Sørensen, HT, 2023) |
| " We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial." | 3.83 | Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Gonzalez-Valcarcel, J; Hennerici, MG; Labreuche, J; Mattle, HP; Rothwell, PM; Sissani, L; Steg, PG; Vicaut, E, 2016) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| " The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality." | 2.90 | Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. ( Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K, 2019) |
| "Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs)." | 2.74 | Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. ( Becker, MC; Borer, JS; Graham, DY; Husni, ME; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Mascette, AM; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, TH; Wisniewski, L; Wolski, K; Yeomans, ND, 2009) |
| "Among their beneficial effects, non-steroidal anti-inflammatory drugs may also exert several side effects which depend on the dosage and the type of these medications." | 2.52 | [Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous]. ( Horváth, VJ; Koós, CG; Lakatos, P; Putz, Z; Szabó, G; Tabák, GÁ, 2015) |
| "Ibuprofen risk was seen only with higher doses." | 2.47 | Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. ( Henry, D; McGettigan, P, 2011) |
| " These results suggest that even the acute use of an NSAID (regardless of COX-2 selectivity) can induce gastric damage when combined with the long-term use of low-dose aspirin in an animal model." | 1.43 | Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy. ( Baglie, S; Baller, EM; Franco, GC; Gevert, MV; Lupepsa, AC; Moro, MG; Sanchez, PK; Tostes, AF, 2016) |
| "Metformin is an antihyperglycemic agent commonly used in diabetic patients." | 1.37 | The nephrologist's role in metformin-induced lactic acidosis. ( Basterrechea, MA; de Arriba, G; Gómez-Navarro, L; Hernández-Sevillano, B; Pérez del Valle, KM; Rodríguez-Palomares, JR; Sánchez-Heras, M; Tallón, S; Torres-Guinea, M, 2011) |
| " Etoricoxib is partly metabolised by the cytochrome P450 isoenzyme CYP 3A4 and increases the bioavailability of ethinylestradiol." | 1.34 | Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. ( , 2007) |
| "Treatment with ibuprofen might limit the cardioprotective effects of aspirin." | 1.32 | Effect of ibuprofen on cardioprotective effect of aspirin. ( MacDonald, TM; Wei, L, 2003) |
| " We explore the toxicities of OTC cough and cold medications, discuss mechanisms of dosing errors, and suggest why physicians should be more vigilant in specifically inquiring about OTCs when evaluating an ill child." | 1.31 | Toxicity of over-the-counter cough and cold medications. ( Gunn, VL; Liebelt, EL; Serwint, JR; Taha, SH, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.79) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 27 (48.21) | 29.6817 |
| 2010's | 19 (33.93) | 24.3611 |
| 2020's | 8 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Obeid, S | 1 |
| Libby, P | 4 |
| Husni, E | 1 |
| Wang, Q | 3 |
| Wisniewski, LM | 3 |
| Davey, DA | 1 |
| Wolski, KE | 3 |
| Xia, F | 1 |
| Bao, W | 3 |
| Walker, C | 1 |
| Ruschitzka, F | 3 |
| Nissen, SE | 5 |
| Lüscher, TF | 4 |
| Zhou, C | 1 |
| Wu, Q | 1 |
| Ye, Z | 1 |
| Zhang, Y | 3 |
| Yang, S | 1 |
| Liu, M | 1 |
| He, P | 1 |
| Qin, X | 1 |
| van Ham, WB | 1 |
| Cornelissen, CM | 1 |
| van Veen, TAB | 1 |
| Minhas, D | 3 |
| Nidhaan, A | 3 |
| Husni, ME | 7 |
| Wei, J | 1 |
| Zeng, C | 1 |
| Lane, NE | 1 |
| Li, X | 1 |
| Lei, G | 1 |
| Bonnesen, K | 1 |
| Pedersen, L | 2 |
| Ehrenstein, V | 1 |
| Grønkjær, MS | 1 |
| Sørensen, HT | 2 |
| Hallas, J | 2 |
| Lash, TL | 1 |
| Schmidt, M | 3 |
| Ernst, MT | 1 |
| Pottegård, A | 1 |
| Vaja, R | 1 |
| Chan, JSK | 1 |
| Ferreira, P | 1 |
| Harky, A | 1 |
| Rogers, LJ | 1 |
| Gashaw, HH | 1 |
| Kirkby, NS | 1 |
| Mitchell, JA | 1 |
| Raschle, J | 1 |
| Ganju, J | 1 |
| Rom, D | 1 |
| Solomon, DH | 4 |
| Borer, JS | 3 |
| Graham, DY | 3 |
| Lincoff, AM | 3 |
| Menon, V | 2 |
| Yeomans, ND | 3 |
| Berger, MF | 2 |
| Prozzi, GR | 1 |
| Cañás, M | 1 |
| Urtasun, MA | 1 |
| Buschiazzo, HO | 1 |
| Dorati, CM | 1 |
| Mordujovich-Buschiazzo, P | 1 |
| Shao, M | 1 |
| Wolski, K | 2 |
| Nissen, S | 1 |
| Paynter, N | 1 |
| Reed, GW | 1 |
| Sifferlin, A | 1 |
| Moore, N | 1 |
| Salvo, F | 1 |
| Duong, M | 1 |
| Blin, P | 1 |
| Pariente, A | 1 |
| Harbin, M | 1 |
| Turgeon, RD | 1 |
| Kolber, MR | 1 |
| Horváth, VJ | 1 |
| Tabák, GÁ | 1 |
| Szabó, G | 1 |
| Putz, Z | 1 |
| Koós, CG | 1 |
| Lakatos, P | 1 |
| Gonzalez-Valcarcel, J | 1 |
| Sissani, L | 1 |
| Labreuche, J | 1 |
| Bousser, MG | 1 |
| Chamorro, A | 1 |
| Fisher, M | 1 |
| Ford, I | 1 |
| Fox, KM | 1 |
| Hennerici, MG | 1 |
| Mattle, HP | 1 |
| Rothwell, PM | 1 |
| Steg, PG | 1 |
| Vicaut, E | 1 |
| Amarenco, P | 1 |
| Moro, MG | 1 |
| Sanchez, PK | 1 |
| Gevert, MV | 1 |
| Baller, EM | 1 |
| Tostes, AF | 1 |
| Lupepsa, AC | 1 |
| Baglie, S | 1 |
| Franco, GC | 1 |
| Gaffney, M | 1 |
| Beckerman, B | 1 |
| González-Gay, MA | 1 |
| González-Juanatey, C | 1 |
| Castelli, G | 1 |
| Petrone, A | 1 |
| Xiang, J | 1 |
| Shrader, C | 1 |
| King, D | 1 |
| Becker, MC | 1 |
| Wang, TH | 1 |
| Wisniewski, L | 1 |
| Mascette, AM | 1 |
| Krum, H | 1 |
| Ray, WA | 1 |
| Varas-Lorenzo, C | 2 |
| Chung, CP | 1 |
| Castellsague, J | 2 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Gómez-Navarro, L | 1 |
| de Arriba, G | 1 |
| Sánchez-Heras, M | 1 |
| Pérez del Valle, KM | 1 |
| Hernández-Sevillano, B | 1 |
| Basterrechea, MA | 1 |
| Tallón, S | 1 |
| Torres-Guinea, M | 1 |
| Rodríguez-Palomares, JR | 1 |
| McGettigan, P | 1 |
| Henry, D | 1 |
| MacDonald, TM | 2 |
| Wei, L | 2 |
| Mainous, AG | 1 |
| Pearson, WS | 1 |
| Etminan, M | 1 |
| Samii, A | 1 |
| Smout, J | 1 |
| Cleanthis, M | 1 |
| Stansby, G | 1 |
| Jerie, P | 1 |
| Weiss, HJ | 1 |
| Curtis, JP | 1 |
| Krumholz, HM | 1 |
| Cross, PL | 1 |
| Hillarp, A | 1 |
| Gaziano, JM | 1 |
| Gibson, CM | 1 |
| Motsko, SP | 1 |
| Rascati, KL | 1 |
| Busti, AJ | 1 |
| Wilson, JP | 1 |
| Barner, JC | 1 |
| Lawson, KA | 1 |
| Worchel, J | 1 |
| Sibbald, B | 1 |
| Maguire, A | 1 |
| Perez-Gutthann, S | 1 |
| Flipo, RM | 1 |
| Farkouh, ME | 1 |
| Greenberg, JD | 1 |
| Jeger, RV | 1 |
| Ramanathan, K | 1 |
| Verheugt, FW | 1 |
| Chesebro, JH | 1 |
| Kirshner, H | 1 |
| Hochman, JS | 1 |
| Lay, CL | 1 |
| Ruland, S | 1 |
| Mellein, B | 1 |
| Matchaba, PT | 1 |
| Fuster, V | 1 |
| Abramson, SB | 1 |
| Wehrmacher, WH | 1 |
| Messmore, HL | 1 |
| Haque, W | 1 |
| Hennekens, CH | 1 |
| Borzak, S | 1 |
| Purcell, H | 1 |
| Hogan, DB | 1 |
| Campbell, NR | 1 |
| Jennett, P | 1 |
| MacLeod, N | 1 |
| Brant, R | 1 |
| Tive, L | 1 |
| Gunn, VL | 1 |
| Taha, SH | 1 |
| Liebelt, EL | 1 |
| Serwint, JR | 1 |
| Reicin, AS | 1 |
| Shapiro, D | 1 |
| Sperling, RS | 1 |
| Barr, E | 1 |
| Yu, Q | 1 |
| Miser, WF | 1 |
| Walker, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Use of a Self-Guided Mindfulness Mobile Application to Improve Pain Outcomes in Individuals With Knee Osteoarthritis[NCT03936088] | 75 participants (Actual) | Interventional | 2019-05-02 | Completed | |||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)[NCT01814293] | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to loss of funding. No data was collected.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
13 reviews available for ibuprofen and Cardiovascular Diseases
| Article | Year |
|---|---|
Uremic toxins in chronic kidney disease highlight a fundamental gap in understanding their detrimental effects on cardiac electrophysiology and arrhythmogenesis.
Topics: Animals; Arrhythmias, Cardiac; Cardio-Renal Syndrome; Cardiovascular Diseases; Electrophysiologic Te | 2022 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
The COVID-19 ibuprofen controversy: A systematic review of NSAIDs in adult acute lower respiratory tract infections.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; | 2021 |
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Interacti | 2018 |
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.
Topics: Cardiovascular Diseases; Diclofenac; Humans; Ibuprofen; Nonprescription Drugs; Risk Factors | 2014 |
[Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cardiovascular System; Di | 2015 |
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Humans; Ibuprofen; Nap | 2011 |
[Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism].
Topics: Aspirin; Bleeding Time; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Drug | 2004 |
Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interaction | 2006 |
Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Cyclo | 2006 |
[Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; | 2006 |
Ibuprofen and cardiovascular safety: where do we stand?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2007 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
7 trials available for ibuprofen and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2022 |
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy, | 2017 |
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2018 |
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2019 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2009 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
36 other studies available for ibuprofen and Cardiovascular Diseases
| Article | Year |
|---|---|
Regular use of ibuprofen or paracetamol and incident type 2 diabetes: A prospective cohort study in the UK Biobank.
Topics: Acetaminophen; Adult; Biological Specimen Banks; Cardiovascular Diseases; Cohort Studies; Diabetes M | 2022 |
Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Ibuprofen; Naprox | 2023 |
Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross-Over Studies; Diclofe | 2023 |
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Diclofenac; Heart | 2023 |
Non-inferiority versus superiority drug claims: the (not so) subtle distinction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2017 |
Diclofenac use and cardiovascular risks: series of nationwide cohort studies.
Topics: Acetaminophen; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort | 2018 |
NSAID choice: lessons from PRECISION.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Napr | 2019 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase | 2013 |
Cardiovascular safety of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclo | 2014 |
NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclo | 2016 |
Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Brain Ischemia; Cardiovascular Diseases; Female; Hemo | 2016 |
Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cycl | 2016 |
Inflammation: NSAIDs and cardiovascular risk in arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Humans; Ibup | 2017 |
Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009-2010.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross-Sectional Studies; Fe | 2017 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
The nephrologist's role in metformin-induced lactic acidosis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibi | 2011 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2003 |
Aspirin and ibuprofen: potential mediators of the cardiovascular risk due to smoking?
Topics: Adolescent; Adult; Aged; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Data Collection; Fema | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Epidem | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Eviden | 2003 |
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Stu | 2006 |
Ibuprofen should go behind-the-counter says expert panel.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Canada; Cardiovascular Diseases; Drug Prescriptions; Health | 2006 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Pain, analgesics, and the cardiovascular system.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Gastr | 2006 |
Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Clinical | 2007 |
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2008 |
Exercise caution when taking ibuprofen. High doses of ibuprofen have been associated with an increased risk of cardiovascular events. How much is safe?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug-Related Side Effects and Adve | 2007 |
Increased use of cardiovascular medications in seniors prescribed non-ASA non-steroidal anti-inflammatory drugs.
Topics: Age Factors; Aged; Alberta; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Humans | 1996 |
Toxicity of over-the-counter cough and cold medications.
Topics: Acetaminophen; Antitussive Agents; Bradycardia; Brompheniramine; Cardiovascular Diseases; Child, Pre | 2001 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |
An aspirin a day keeps the MI away (for some).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Antagonism; H | 2002 |
New drugs and new treatments.
Topics: Administration, Topical; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Car | 1975 |